The global HIV response stands at a crossroads. Pre-exposure prophylaxis (PrEP)—one of the most effective tools in HIV prevention—has achieved remarkable scientific progress, yet access remains deeply inequitable and is now at a heightened threat to further be underfunded or not funded at all. By the end of 2024, approximately 8 million people had initiated
PrEP in 2025: Bridging the Gap Between Innovation and Access
